Education
About Us
Working with TipRanks
Follow Us
BioNxt Solutions (BNXTF)
OTHER OTC:BNXTF
BNXTF Stock Chart & Stats
$0.44
$0.02(7.93%)
At close: 4:00 PM EST
$0.44
$0.02(7.93%)
Day’s Range― - ―
52-Week Range$0.20 - $0.80
Previous CloseN/A
Volume333.00
Average Volume (3M)3.75K
Market Cap
$53.44M
Enterprise Value$72.06M
Total Cash (Recent Filing)$468.76K
Total Debt (Recent Filing)$8.33M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding121,810,260
10 Day Avg. Volume3,336
30 Day Avg. Volume3,755
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)-5.39
Price to Sales (P/S)1568.84
P/FCF Ratio-13.95
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue4.55K
Enterprise Value/Gross Profit-5.76K
Enterprise Value/Ebitda-14.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioNxt Solutions News
BNXTF FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was $0.20 and its highest was $0.80 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is $53.44M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Apr 29, 2026 which is in 124 days.
How were BioNxt Solutions’s earnings last quarter?
BioNxt Solutions released its earnings results on Nov 26, 2025. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 121,810,260 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
BioNxt Solutions reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.167%.
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in BNXTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Mountain Valley MD
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Revive Therapeutics
―
InnoCan Pharma
―
Ownership Overview
Options Prices
Currently, No data available
---